STOCK TITAN

Aimei Health Technology Co. (AFJK) DEF 14A Filings

AFJK NASDAQ

Here are the DEF 14A proxy statements from Aimei Health Technology Co., Ltd (AFJK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow AFJK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AFJK filings page.

Rhea-AI Summary

Aimei Health Technology Co., Ltd. (AFJK) seeks approval for Articles and trust-agreement amendments that would extend its business-combination period from 36 to 48 months, moving the deadline from December 6, 2026, to as late as December 6, 2027. If approved, each monthly extension requires the Sponsor to deposit the lesser of $80,000 for all outstanding Public Shares or $0.033 per outstanding Public Share. Shareholders also vote on MaloneBailey, LLP as auditor for the year ending December 31, 2026, and possible adjournment at the November 10, 2026 meeting.

The United Hydrogen transaction was terminated on July 7, 2026, because required China Securities Regulatory Commission approval had not been obtained as of July 6, 2026; AFJK says it is evaluating new targets. Approval of the Articles amendment would trigger an offer to redeem Public Shares; the estimated per-share redemption value was approximately $12.25 per Public Share as of October 2, 2026, with a November 6, 2026 tender deadline.

As of October 2, 2026, the Sponsor, directors, executive officers and affiliates beneficially owned and were entitled to vote 2,057,000 ordinary shares, approximately 64.96% of shares outstanding, and were expected to support all four proposals. The Articles amendment requires two-thirds of votes cast; each other proposal requires a simple majority.